CTOs on the Move

The VGM Group

www.vgm.com

 
The VGM Group is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Waterloo, IA. To find more information about The VGM Group, please visit www.vgm.com
  • Number of Employees: 0-25
  • Annual Revenue: $50-100 Million
  • www.vgm.com

  • Waterloo, IA USA 50701-9007
  • Phone: 319.236.7270

Executives

Name Title Contact Details
Jeff Hickey
Vice president of IT Operations Profile
Jay Bracken
Information Security Officer Profile

Similar Companies

g.b.cooley hospital service district

g.b.cooley hospital service district is a Monroe, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ortho Arkansas

Ortho Arkansas is a Little Rock, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pana Community Hospital

Since 1914, Pana Community Hospital has been a place for quality health care. Our employees, medical staff, board of directors and management continue to strengthen and expand our hospital and its’ services. We are committed to your health care future, making our hospital a place you can count on. You can be sure our focus is on today and tomorrow…always striving to bring you quality health care close to home! Our Mission is to be a leading partner in assuring community-based quality Healthcare.

Rovin Med,

Rovin Med, is a Plainfield, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Furiex

Furiex Pharmaceuticals, Inc., a drug development company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company’s products under development include Eluxadoline1, a mu opioid receptor agonist and delta opioid receptor antagonist, which is in Phase III clinical trials for the treatment of diarrhea-predominant irritable bowel syndrome; and Avarofloxacin1, a Phase III-ready fluoroquinolone antibiotic for the treatment of acute bacterial skin and skin structure infections. It is also developing SYR-472, which is in Phase III clinical trials for the treatment of Type-2 diabetes. In addition, the company has rights to compounds in various stages of development and commercialization, which includes Nesina, Liovel, Oseni, and Kazano for the treatment of Type-2 diabetes, as well as Priligy for the treatment of premature ejaculation. The company was founded in 1998 and is headquartered in Morrisville, North Carolina.